-$0.12 EPS Expected for Galectin Therapeutics Inc. (GALT) This Quarter

Wall Street analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to post earnings per share (EPS) of ($0.12) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Galectin Therapeutics’ earnings. Galectin Therapeutics reported earnings of ($0.07) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 71.4%. The company is scheduled to issue its next quarterly earnings report on Thursday, April 4th.

On average, analysts expect that Galectin Therapeutics will report full year earnings of ($0.44) per share for the current year. For the next financial year, analysts forecast that the company will report earnings of ($1.12) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Galectin Therapeutics.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02.

A number of equities research analysts recently commented on the company. ValuEngine lowered Galectin Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 26th. BidaskClub upgraded Galectin Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Galectin Therapeutics in a research report on Thursday, August 16th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $10.00.

GALT stock opened at $4.97 on Wednesday. Galectin Therapeutics has a 1-year low of $1.80 and a 1-year high of $9.49.

In related news, Director Gilbert S. Omenn sold 19,370 shares of the stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $6.02, for a total transaction of $116,607.40. Following the sale, the director now directly owns 56,561 shares in the company, valued at approximately $340,497.22. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 38.80% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GALT. Millennium Management LLC bought a new stake in Galectin Therapeutics during the 1st quarter worth approximately $454,000. Belpointe Asset Management LLC bought a new stake in Galectin Therapeutics during the 2nd quarter worth approximately $277,000. First Allied Advisory Services Inc. bought a new stake in Galectin Therapeutics during the 2nd quarter worth approximately $223,000. BlackRock Inc. grew its position in Galectin Therapeutics by 199.9% during the 2nd quarter. BlackRock Inc. now owns 588,308 shares of the company’s stock worth $3,742,000 after acquiring an additional 392,151 shares during the last quarter. Finally, ING Groep NV bought a new stake in Galectin Therapeutics during the 2nd quarter worth approximately $318,000. Institutional investors and hedge funds own 14.36% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.

See Also: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Galectin Therapeutics (GALT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply